---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-018333"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2026-02-23T23:59:59+00:00"
generated_at: "2026-05-16T01:21:06.146924+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FDA grants QIDP designation to Armata's AP-SA02 for S. aureus bacteremia

## Summary
- AP-SA02 receives QIDP for intravenous adjunct treatment of complicated MSSA/MRSA bacteremia.
- QIDP provides five-year Hatch-Waxman market exclusivity extension and eligibility for Fast Track.
- CEO Dr. Deborah Birx says Phase 3 superiority study planned to start in H2 2026.
- Company intends to submit a request for Fast Track Designation for AP-SA02 to FDA.

## SEC filing metadata
- accession: 0001104659-26-018333
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2026-02-23T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465926018333/0001104659-26-018333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465926018333/tm267017d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-018333
- JSON: https://secwatch.observer/filing/0001104659-26-018333.json
- Plain text: https://secwatch.observer/filing/0001104659-26-018333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.